Skip to content

Effect of clonidine on the target dose of propofol: bispectral index evaluation

Effect of clonidine on the target dose of propofol: bispectral index evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-84b9cd
Enrollment
Unknown
Registered
2015-06-25
Start date
2013-03-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cholelithiasis, clonidine

Interventions

Experimental group: 26 patients undergoing laparoscopic cholecystectomy or jaw fracture treatment under total intravenous anesthesia. Received 3 mcg / kg of clonidine administered in 100 ml of saline,
Drug

Sponsors

Faculdade de Medicina do ABC
Lead Sponsor
Faculdade de Medicina do ABC
Collaborator

Eligibility

Age
15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients ASA I or II. Scheduled for laparoscopic cholecystectomy or jaw fracture treatment in Cariri Regional Hospital. Signing the consent form. Age between 15 and 65 years. Sample : 51 patients.

Exclusion criteria

Exclusion criteria: Drug users who can interfere in the outcomes. Drug Addicts. Physical state above two. Refusal to sign the Instrument of Consent.

Design outcomes

Primary

MeasureTime frame
"Expected outcome: reduction in propofol target dose in the group using clonidine.";Evidenced outcome: The outcome was evidenced by the reduction in target dose of propofol in the group receiving clonidine at a p <0.001. The reduction in propofol target dose was approximately 50% clonidine. Expected outcome: reduction in propofol target dose in the group using clonidine.

Secondary

MeasureTime frame
Expected outcome: reduction in propofol target dose.;Evidenced outcome: reduction in propofol target dose by approximately 50% in the group using clonidine premedication.

Countries

Brazil

Contacts

Public Contacthermes;Luiz batista;de Abreu

Hospital Regional do Cariri;Faculdade de Medicina do ABC

hermesmelo@oi.com.br;cdh.fsp@gmail.com8899280669;+55(11)983264503

Outcome results

None listed

Source: REBEC (via WHO ICTRP)